Conference Track

New Advances in Hepatitis C

Source: CCO Independent Conference Coverage of the 2008 Annual Meeting of the European Association for the Study of the Liver*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

COPILOT Final Results: Maintenance Therapy With Peginterferon Alfa-2b Associated With Improved Event-Free Survival in Patients With Cirrhosis and Portal Hypertension
RVR a Better Predictor of SVR Than HCV Genotype in HCV-Infected Patients With Peginterferon alfa-2a Plus Ribavirin
HCV Genotype 2/3 Patients With Low Baseline Platelet Count or High BMI Should Not Receive Shortened 12-Week Course of Peginterferon alfa-2b plus Weight-Based Ribavirin due to Higher Rates of Relapse
Cirrhosis Regression During HCV Therapy Associated With Improved Liver-Related Morbidity, Mortality During Long-term Follow-up
Peginterferon Maintenance Therapy not Associated With a Reduced Risk of HCC in HALT-C Trial
HALT-C: Prolonged Low-Dose Peginterferon alfa-2a Maintenance Therapy in Absence of Viral Suppression Not Associated With Improved Liver Histology, Clinical Outcomes
Sustained Virologic Response Associated With Regression of Liver Disease, Improved Survival in Patients With HCV
Factors Associated With Null Response to Peginterferon/Ribavirin in Genotype 1 HCV–Infected Patients Identified
Time to HCV RNA Undetectability Best Predictor of SVR in Patients With Genotype 1 HCV
Factors Predicting SVR With Peginterferon alfa-2b/Ribavirin Retreatment in Previous Nonresponders and Relapsers: Final Results From EPIC3
Single-Center Study: Higher SVR Rates With Peginterferon alfa-2a vs Peginterferon alfa-2b in Patients With High HCV RNA and Genotype 1 Infection
IDEAL: Weight-Based Peginterferon alfa-2b and Fixed-Dose Peginterferon alfa-2a–Based Therapies Induce Similar SVR Rates in Genotype 1 HCV–Infected Patients

Expert Analysis

New Advances in Hepatitis C

Faculty:

Alfredo Alberti, MD
Peter Ferenci, MD
Michael P. Manns, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Recount data comparing the efficacy of different formulations of peginterferon in hepatitis C virus infection
Summarize data regarding the efficacy of various regimens for retreatment of previous nonresponders and relapsers
Discuss findings regarding the utility of low-dose maintenance therapy in hepatitis C patients
Describe data evaluating predictors of response to hepatitis C therapy

CME CREDIT INFORMATION

Release Date: 06/25/08

Expiration Date: 06/24/09

Physicians: maximum of 1.25 AMA PRA Category 1 Credits™

Registered Nurses: 1.2 Nursing CE credits

Pharmacists: 1.2 contact hours (0.12 CEUs)

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.